Headlines

Amgen (AMGN) Q4 2025 (USD): Adj. EPS 5.29 (exp. 4.73), Revenue 9.87bln (exp. 9.47bln)

Newsquawk Staff ·

  • Operating income 4.0bln (exp. 3.64bln).

Outlook

  • FY adj. EPS 21.60-23.00 (exp. 22.13).
  • FY revenue 37-38.4bln (exp. 37.2bln).
  • FY26 share repurchases not to exceed USD 3bln.
  • To initiate phase 3 studies of maritide in people living with type 2 Diabetes in 2026

What it means

Amgen's Q4 2025 results exceeded expectations, with both adjusted EPS and revenue coming in higher than anticipated. This positive performance, coupled with an optimistic forward outlook on annual EPS and revenue, suggests strong operational momentum and could bolster confidence among investors, particularly as the company initiates new phase 3 studies that may enhance its pipeline.

Related headlines